舒血宁联合马来酸桂哌齐特治疗急性脑梗死的临床疗效

Curative effect of Shuxuening combined with cinepazide maleate in the treatment of acute cerebral infarction

目的探讨舒血宁联合马来酸桂哌齐特治疗急性脑梗死的临床疗效。方法选择2015年7月至2016年9月72例急性脑梗死患者均分为对照组与研究组各36例。对照组患者接受舒血宁治疗,研究组患者在此基础上联用马来酸桂哌齐特治疗。比较两组患者的NIHSS评分及临床疗效。结果研究组用药后5 d、10 d、20 d时的NIHSS评分改善较对照组更优,差异具有统计学意义(P<0.05);研究组患者治疗总有效率97.2%,明显高于对照组患者治疗总有效率77.8%,差异有统计学意义(P<0.05);两组患者不良反应均较轻微,停药后缓解。结论舒血宁联合马来酸桂哌齐特治疗急性脑梗死效果满意,安全性较高。

Objective To analyze the effect of Shuxuening combined with cinepazide maleate in the treatment of acute cerebral infarction.Methods 72 cases of patients with acute cerebral infarction from July 2015 to September 2016 were divided into control group and experimental group, 36 cases in each group. The control group was given Shuxuening, The experimental group was treated with Cinepazide Maleate combined with Shuxuening. The HIHSS scores and clinical efficacy of the two groups was observed.Results 5d, 10d and 20d after administration of treatment the NIHSS score of experimental group improved more than the control group, there was statistical significance（ P〈0.05 ）. The total effective rate of experimental group was 97.2% , significantly higher than 77.8% of the control group （P〈0.05）. The difference of adverse reaction rate between the two groups had no statistical significance （P〉 0. 05）. Conclusions Shuxuening combined with cinepazide maleate in the treatment of acute cerebral infarction with satisfactory effect and high safety.